Compounded drug products are being voluntarily recalled due a lack of sterility assurance.
List view / Grid view
Filter the results
A jury has said that Johnson & Johnson must pay $8 billion in the case over male breast growth linked to Risperdal.
The UK MHRA has issued an alert for the recall of unexpired Zantac products made by GSK due to the possible contamination of ranitidine in the medicines.
The FDA recommends drug manufacturers to use LC-HRMS to test for NDMA in ranitidine products, as high temperatures generate the impurity.
The FDA and DEA have, for the first time, sent joint warning letters to four networks which were illegally selling opioid products.
Johnson & Johnson have reached a settlement with two Ohio counties over its role in the opioid crisis, removing the company from the trial due to begin later this month.
Drugmakers that face litigation over the opioid crisis are looking at ways to settle the cases by using Purdue's bankruptcy, it has been reported.
The European Medicines Agency has issued advice to pharmaceutical companies on how to avoid the presence of nitrosamines in medicines.
The drug daratumumab has been approved for treatment of multiple myeloma, demonstrating increased efficacy when used in combination with other drugs.
The probable carcinogen N-nitrosodimethylamine was detected in Sandoz’s ranitidine capsules, prompting the voluntary move.
FDA announces the voluntary recall for the losartan medications has been extended to include more lots, after impurities were found in the drugs.
The British Pharmacopoeia and United States Pharmacopeia partnership is to be formalised to strengthen the quality of medicines and public health.
Darmerica LLC is voluntarily recalling two lots of quinacrine dihydrochloride due to a label mix-up.
Pharmaceutical Manufacturing Research Services has filed a lawsuit against the FDA after it rejected its application for opioids with updated labelling and appearance, meant to discourage misuse.